Jordan and Meadows Raise Questions about Cummings’s Drug Pricing Investigation

Published: Apr 5, 2019

WASHINGTON, DC – Today, Congressman Jim Jordan (R-OH), Ranking Member of the Committee on Oversight and Reform, and Congressman Mark Meadows (R-NC), Ranking Member of the Government Operations Subcommittee, sent letters to twelve pharmaceutical companies targeted by Chairman Cummings’s sweeping drug price investigation.
Excerpts from the letter: 
“Although addressing rising drug prices should be a bipartisan issue, Chairman Cummings did not consult with Republican Members before launching his investigation. Now, in light of Chairman Cummings’s recent boast that his investigation has affected pharmaceutical “stock prices”-and the Chairman’s decision to unilaterally release sensitive information obtained by the Committee in another investigation-we feel obliged to inform you about these matters.”
“While we cannot speculate about Chairman Cummings’s motives, we believe the Committee should not pursue an investigation to ‘impact . . . stock prices with regard to drugs’-especially when there is bipartisan interest in real oversight of rising prescription drug prices.”
Full text of the letters can be found here.